[Prevention recommendations for transgender persons].

Transgender people are at risk of being in worse health than the cisgender population. On the one hand, they encounter specific health problems, mostly related to the impact of minority stress on their mental and somatic health. On the other hand, the preventive recommendations usually do not account for gender-affirming hormonal or surgical treatments that can alter their biologic or anatomic risk profile.

[Deep vein thrombosis: new developments and recommendations for the primary care physician].

The management of deep vein thrombosis is becoming more specific in terms of diagnostic methods and drug treatments. The use of the dichotomous Wells' score is now established. The indications for direct oral anticoagulants have expanded.

[Gender and sexual diversity medicine:ensuring equity in health care delivery].

The literature on the subject systematically shows that LGBTIQ+ people suffer from a worse health status than heterosexual and cisgender people. They are subject to more medical errors, discriminations, and delays in receiving care. They face many specific barriers in their access to care.

Multimorbidity and clinical reasoning through the eyes of GPs: a qualitative study.

Objectives: Despite the high prevalence of patients suffering from multimorbidity, the clinical reasoning processes involved during the longitudinal management are still sparse.This study aimed to investigate what are the different characteristics of the clinical reasoning process clinicians use with patients suffering from multimorbidity, and to what extent this clinical reasoning differs from diagnostic reasoning.

Design: Given the exploratory nature of this study and the difficulty general practitioners (GPs) have in expressing their reasoning, a qualitative methodology was therefore, chosen.

[The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].

Type 2 diabetes therapy has expanded considerably over the last decade. Two anti-diabetic therapeutic groups, which are GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 inhibitors (sodium-glucose co-transporter-2), have shown efficacy not only on glycemic control but also on weight and other parameters that will be detailed in this article. Cardiovascular safety studies for two of these molecules were shown for the first time to decrease overall and cardiovascular mortality.